Engineering and identifying supercharged proteins for macromolecule delivery into mammalian cells.

Supercharged proteins are a class of engineered or naturally occurring proteins with unusually high positive or negative net theoretical charge. Both supernegatively and superpositively charged proteins exhibit a remarkable ability to withstand thermally or chemically induced aggregation. Superpositively charged proteins are also able to penetrate mammalian cells. Associating cargo with these proteins, such as plasmid DNA, siRNA, or other proteins, can enable the functional delivery of these macromolecules into mammalian cells both in vitro and in vivo. The potency of functional delivery in some cases can exceed that of other current methods for macromolecule delivery, including the use of cell-penetrating peptides such as Tat and adenoviral delivery vectors. This chapter summarizes methods for engineering supercharged proteins, optimizing cell penetration, identifying naturally occurring supercharged proteins, and using these proteins for macromolecule delivery into mammalian cells.

[1]  Frances H. Arnold,et al.  Molecular evolution by staggered extension process (StEP) in vitro recombination , 1998, Nature Biotechnology.

[2]  H. Ruley,et al.  Epigenetic regulation of gene structure and function with a cell-permeable Cre recombinase , 2001, Nature Biotechnology.

[3]  Subashini Asokan,et al.  Effective gene silencing by multilayered siRNA-coated gold nanoparticles. , 2011, Small.

[4]  H. Mizusawa,et al.  Efficient in vivo delivery of siRNA to the liver by conjugation of alpha-tocopherol. , 2008, Molecular therapy : the journal of the American Society of Gene Therapy.

[5]  A. Brayman,et al.  Ultrasound with microbubbles enhances gene expression of plasmid DNA in the liver via intraportal delivery , 2008, Gene Therapy.

[6]  A. Karshikoff,et al.  Ion pairs and the thermotolerance of proteins from hyperthermophiles: a "traffic rule" for hot roads. , 2001, Trends in biochemical sciences.

[7]  Douglas A. Melton,et al.  In vivo reprogramming of adult pancreatic exocrine cells to β-cells , 2008, Nature.

[8]  T. Restle,et al.  Cellular delivery of small interfering RNA by a non-covalently attached cell-penetrating peptide: quantitative analysis of uptake and biological effect , 2006, Nucleic acids research.

[9]  David R. Liu,et al.  Potent Delivery of Functional Proteins into Mammalian Cells in Vitro and in Vivo Using a Supercharged Protein , 2010, ACS chemical biology.

[10]  David R. Liu,et al.  Supercharging proteins can impart unusual resilience. , 2007, Journal of the American Chemical Society.

[11]  Ű. Langel,et al.  Characterization of bioactive cell penetrating peptides from human cytochrome c: protein mimicry and the development of a novel apoptogenic agent. , 2010, Chemistry & biology.

[12]  S. Dowdy,et al.  Revised Role of Glycosaminoglycans in TAT Protein Transduction Domain-mediated Cellular Transduction , 2009, The Journal of Biological Chemistry.

[13]  Michelle R. Arkin,et al.  Small-molecule inhibitors of protein–protein interactions: progressing towards the dream , 2004, Nature Reviews Drug Discovery.

[14]  K. Dill,et al.  The Protein Folding Problem , 1993 .

[15]  W. Stemmer,et al.  Single-step assembly of a gene and entire plasmid from large numbers of oligodeoxyribonucleotides. , 1995, Gene.

[16]  Tina N. Davis,et al.  A class of human proteins that deliver functional proteins into mammalian cells in vitro and in vivo. , 2011, Chemistry & biology.

[17]  K. G. Rajeev,et al.  Targeted Delivery of RNAi Therapeutics With Endogenous and Exogenous Ligand-Based Mechanisms. , 2010, Molecular therapy : the journal of the American Society of Gene Therapy.

[18]  David R. Liu,et al.  Cellular uptake mechanisms and endosomal trafficking of supercharged proteins. , 2012, Chemistry & biology.

[19]  T. Minko,et al.  Internally cationic polyamidoamine PAMAM-OH dendrimers for siRNA delivery: effect of the degree of quaternization and cancer targeting. , 2009, Biomacromolecules.

[20]  C. Cepko,et al.  Controlled expression of transgenes introduced by in vivo electroporation , 2007, Proceedings of the National Academy of Sciences.

[21]  R. Raines,et al.  Onconase cytotoxicity relies on the distribution of its positive charge , 2009, The FEBS journal.

[22]  Joost Schymkowitz,et al.  The stability effects of protein mutations appear to be universally distributed. , 2007, Journal of molecular biology.

[23]  S. Cryan,et al.  Inhalable siRNA: potential as a therapeutic agent in the lungs. , 2008, Molecular pharmaceutics.

[24]  Robert Langer,et al.  A combinatorial library of lipid-like materials for delivery of RNAi therapeutics , 2008, Nature Biotechnology.

[25]  M. Hensel,et al.  Small interfering RNA (siRNA) delivery into murine bone marrow-derived dendritic cells by electroporation. , 2008, Journal of immunological methods.

[26]  Steven F Dowdy,et al.  Transducible TAT-HA fusogenic peptide enhances escape of TAT-fusion proteins after lipid raft macropinocytosis , 2004, Nature Medicine.

[27]  F. Arnold,et al.  Functional and nonfunctional mutations distinguished by random recombination of homologous genes. , 1997, Proceedings of the National Academy of Sciences of the United States of America.

[28]  T. Niidome,et al.  In vivo siRNA delivery with dendritic poly(L-lysine) for the treatment of hypercholesterolemia. , 2009, Molecular bioSystems.

[29]  Ronald T. Raines,et al.  Arginine grafting to endow cell permeability. , 2007, ACS chemical biology.

[30]  David R. Liu,et al.  Mammalian cell penetration, siRNA transfection, and DNA transfection by supercharged proteins , 2009, Proceedings of the National Academy of Sciences.

[31]  P. Stahl,et al.  Receptor-mediated endocytosis of transferrin and recycling of the transferrin receptor in rat reticulocytes , 1983, The Journal of cell biology.

[32]  Matthias John,et al.  Therapeutic silencing of an endogenous gene by systemic administration of modified siRNAs , 2004, Nature.

[33]  F. Akdim,et al.  Effect of mipomersen, an apolipoprotein B synthesis inhibitor, on low-density lipoprotein cholesterol in patients with familial hypercholesterolemia. , 2010, The American journal of cardiology.

[34]  Shizuo Akira,et al.  Innate Antiviral Responses by Means of TLR7-Mediated Recognition of Single-Stranded RNA , 2004, Science.

[35]  C. Yanisch-Perron,et al.  Improved M13 phage cloning vectors and host strains: nucleotide sequences of the M13mp18 and pUC19 vectors. , 1985, Gene.

[36]  John P. Overington,et al.  How many drug targets are there? , 2006, Nature Reviews Drug Discovery.

[37]  D. Ladant,et al.  A bacterial two-hybrid system based on a reconstituted signal transduction pathway. , 1998, Proceedings of the National Academy of Sciences of the United States of America.

[38]  H. Mizusawa,et al.  Efficient In Vivo Delivery of siRNA to the Liver by Conjugation of α-Tocopherol. , 2008, Molecular therapy : the journal of the American Society of Gene Therapy.

[39]  Zhuang Liu,et al.  Functionalization of carbon nanotubes via cleavable disulfide bonds for efficient intracellular delivery of siRNA and potent gene silencing. , 2005, Journal of the American Chemical Society.